Peptone raises $2.5M in a seed round led by Hoxton Ventures and including dRx Capital, Founders Factory and angel investors from the UK.

Peptone, a London, UK-based computational physics company, announced securing a funding round of $2.5 million.

The money was raised from investors led by early stage backer from the UK, Hoxton Ventures, and including contributions from dRx Capital, Founders Factory and a number of angel investors including Brent Hoberman.

Proceeds will be used to further develop its groundbreaking technology in order to take on the high-value protein targets and reduce the risk of failure in early stages of drug development.

Peptone, founded in 2017 by protein physicist Dr. Kamil Tamiola and protein engineer Dr. Matt Heberling, developed an AI-tuned protein engineering operating system (PeOS) used to undertake high-value protein targets and reduce the risk of failure early in drug development. By prioritizing the failures of large-scale protein research in the past, Pepton is changing the way major pharmaceutical companies approach the process of developing and engineering life-saving proteins, a fundamental component of modern medicine. Biotechnology companies are accelerating their research in protein biotechnology, thanks to the Protein Engineering Operating System (PeOS), which uses state-of-the-art computational molecular physics coordinated by AI.